TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16935098

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2 g as an intravenous bolus before sternotomy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (from meta-analysis)
Number of subjects: 100
Study: 12903849

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0
Study: 10889591

Group type: EXPERIMENTAL
Intervention: Subcutaneous IL‐2 (7.5 mIU twice per day in 5-day courses every 8 weeks) + ART
Number of subjects: 82

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Subcutaneous IL‐2 + ART
Number of subjects: 82
Study: 9096917

Group type: EXPERIMENTAL
Intervention: Fluvastatin (30 mg/day) added to probucol treatment for 12 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fluvastatin (30 mg/day)
Number of subjects: 27
Study: 8420593

Group type: EXPERIMENTAL
Intervention: Intravenous mCPP (0.1 mg/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral mCPP (0.5 mg/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous mCPP
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral mCPP
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metergoline pretreatment prior to intravenous mCPP
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2868029

Group type: EXPERIMENTAL
Intervention: dipyridamole (Persantine) plus aspirin
Number of subjects: 3128

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3128
Study: 30006262

Group type: EXPERIMENTAL
Intervention: GAF‐ID (internet-based behavioural activation with lay counsellor support)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Online psychoeducation without support
Number of subjects: 313
Study: 27777668

Group type: EXPERIMENTAL
Intervention: Integrated QI curriculum
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (midpoint)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Early intervention group (midpoint)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Late intervention group
Number of subjects: 105
Study: 25415040

Group type: EXPERIMENTAL
Intervention: Support from the central research team
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Importance of the research question
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low child eligibility rates
Number of subjects: 39

Group type: COMPARATOR
Intervention: Integration of trial processes within routine workloads
Number of subjects: 39
Study: 22686966

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 99
Study: 19891665

Group type: EXPERIMENTAL
Intervention: CB-01-05 MMX 210 mg tablets
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 18384882

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 93

Group type: COMPARATOR
Intervention: non‐SSRIs
Number of subjects: 93
Study: 16427529

Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg bolus over 10 minutes, followed by continuous infusion at 1 mg/kg per hour)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl (2.0 microg/kg per hour)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl
Number of subjects: 56

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 56
Study: 12873935

Group type: EXPERIMENTAL
Intervention: IV lidocaine 0.2 mg/kg followed by propofol infusion
Number of subjects: 67

Group type: COMPARATOR
Intervention: IV normal saline (placebo) followed by propofol 1%/lidocaine 1% mixture infusion
Number of subjects: 67
Study: 10469680

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic diagnosis (PGD) for aneuploidy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no PGD)
Number of subjects: 0
Study: 8915224

Group type: EXPERIMENTAL
Intervention: Low-dose ANP (3 pmol/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-dose BNP (3 pmol/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose ANP (10 pmol/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose BNP (10 pmol/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-dose ANP
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose ANP
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-dose BNP
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose BNP
Number of subjects: 8
Study: 1860210

Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (epicardial RV-LV system)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (nonthoracotomy RV-CP system)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (nonthoracotomy CS-RV system)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (RV-LV epicardial patches)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (RV-CP nonthoracotomy system)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Biphasic waveform defibrillation (RV-CS nonthoracotomy system)
Number of subjects: 51
Study: 6341017

Group type: EXPERIMENTAL
Intervention: Maximized insulin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 0
Study: 30796909

Group type: EXPERIMENTAL
Intervention: Hybrid arch bars
Number of subjects: 90

Group type: COMPARATOR
Intervention: Erich arch bars
Number of subjects: 90
Study: 30551315

Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT) + psychoeducation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Psychoeducation + Metacognitive training (MCT)
Number of subjects: 49
Study: 26792933

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg twice a day for 24 weeks
Number of subjects: 54
Study: 24557078

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir-containing regimens
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Baseline bilirubin level of 0.5 mg/dl or higher with hemoglobin concentrations of 14 g/dl or higher
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Baseline bilirubin level <0.5 mg/dl with hemoglobin concentration <14 g/dl
Number of subjects: 542
Study: 22897752

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel (AUC 5/6; 200 mg/m(2))
Number of subjects: 372
Study: 19335497

Group type: EXPERIMENTAL
Intervention: Supplemental perioperative oxygenation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4
Study: 17690808

Group type: EXPERIMENTAL
Intervention: Frequent positive social support
Number of subjects: 1726

Group type: COMPARATOR
Intervention: Negative social support
Number of subjects: 1726

Group type: COMPARATOR
Intervention: Limited positive social support
Number of subjects: 1726
Study: 15576543

Group type: EXPERIMENTAL
Intervention: Innovative multifaceted strategy combining written comparative feedback, group education on national guidelines, and social influence by peers in quality improvement sessions in small groups.
Number of subjects: 194

Group type: COMPARATOR
Intervention: Feedback only
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Innovative multifaceted strategy
Number of subjects: 194
Study: 11457553

Group type: EXPERIMENTAL
Intervention: DTPa-HBV/Hib vaccine administered as a single injection (Group 1)
Number of subjects: 885

Group type: COMPARATOR
Intervention: DTPa-HBV and Hib vaccines administered simultaneously at separate sites (Group 2)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 885
Study: 9734938

Group type: EXPERIMENTAL
Intervention: TNF alpha MAb (7.5 mg/kg)
Number of subjects: 1879

Group type: COMPARATOR
Intervention: Placebo (0.25% human serum albumin)
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: TNF alpha MAb
Number of subjects: 1879

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1879
Study: 7802530

Group type: EXPERIMENTAL
Intervention: Ioxaglate (Iox), an ionic product
Number of subjects: 64

Group type: COMPARATOR
Intervention: Iopamidol (Iop), a non-ionic product
Number of subjects: 64
Study: 3289293

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multiple insulin injections
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional treatment (twice daily injections)
Number of subjects: 45
Study: 29956440

Group type: EXPERIMENTAL
Intervention: Topical EGF ointment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Petrolatum (Control)
Number of subjects: 19
Study: 26628069

Group type: EXPERIMENTAL
Intervention: Training Group (TG) - Auditory training program using a mobile device for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (NTG) - Traditional auditory training for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Training Group (TG) - Auditory training program using a mobile device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (NTG) - Traditional auditory training
Number of subjects: 20
Study: 26583667

Group type: EXPERIMENTAL
Intervention: LCT-EOS >3 mmol/L
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: LCT-EOS cutoff values
Number of subjects: 985
Study: 23921427

Group type: EXPERIMENTAL
Intervention: BOSU trainer
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Airex balance pad
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Half-foam roller
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: DynaDisc
Number of subjects: 57
Study: 21030168

Group type: EXPERIMENTAL
Intervention: Dornase alfa
Number of subjects: 5

Group type: COMPARATOR
Intervention: 0.9% NaCl (normal saline)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dornase alfa and 0.9% NaCl
Number of subjects: 5
Study: 19674280

Group type: EXPERIMENTAL
Intervention: Human intravenous immunoglobulin (hIVIG) 0.5 g/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16989922

Group type: EXPERIMENTAL
Intervention: 16-detector multi-slice CT screening for lung cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study: 12892536

Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study: 10931101

Group type: EXPERIMENTAL
Intervention: High dose short synacthen test (HDT, 250 microgram)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low dose short synacthen test (LDT, 1 microgram)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 30
Study: 9065962

Group type: EXPERIMENTAL
Intervention: WS 1490 (kava-kava extract)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 8147961

Group type: EXPERIMENTAL
Intervention: Zinc + Vitamin A
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Zinc (25 mg/d)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Vitamin A (1500 mg RE/d)
Number of subjects: 140
Study: 3092269

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31718953

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Prasugrel 3.75 mg once daily
Number of subjects: 33
Study: 30340503

Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise intervention (moderate-vigorous, 65-85% heart rate maximum, thrice weekly for 16 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise intervention
Number of subjects: 100
Study: 27346807

Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Intraperitoneal saline
Number of subjects: 76
Study: 24758077

Group type: EXPERIMENTAL
Intervention: Catgut implantation at acupoint for 3 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sulfasalazine Enteric-coated Tablet (SECT), 0.5 g three times daily for 3 months (Control)
Number of subjects: 74
Study: 23047470

Group type: EXPERIMENTAL
Intervention: Test formulation of ciprofloxacin 500 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of ciprofloxacin 500 mg
Number of subjects: 24
Study: 20547163

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Propranolol (up to 320 mg/day)
Number of subjects: 101
Study: 17340594

Group type: EXPERIMENTAL
Intervention: Androgen suppression therapy (AST) and radiation therapy (RT) with 70 Gy and 6 months of AST
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Increasing PSA level
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gleason score 8-10 cancer
Number of subjects: 102
Study: 15827107

Group type: EXPERIMENTAL
Intervention: GH (0.5 mg/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (250 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GH (0.5 mg/d) and Testosterone (250 mg) combined
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study: 12474916

Group type: COMPARATOR
Intervention: Modified fluorescein dye disappearance test (DDT) with 2% fluorescein instilled in the eye; Schirmer tear test strips placed in the lower conjunctival fornix after 3 and 10 minutes.
Number of subjects: 74
Study: 9865428

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (1.01 mg/kg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (2.01 mg/kg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet (0.16 mg/kg/day)
Number of subjects: 12
Study: 7885123

Group type: EXPERIMENTAL
Intervention: Oral captopril (6.25 mg initial dose, 12.5 mg 2 hours later, and then 12.5 mg three times daily)
Number of subjects: 13634

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 13634

Group type: EXPERIMENTAL
Intervention: Oral captopril
Number of subjects: 13634
Study: 2195936

Group type: EXPERIMENTAL
Intervention: Once-daily (OD) theophylline therapy administered in the evening at 8:00 P.M.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional twice-daily (TD) theophylline therapy administered at 8:00 A.M. and 8:00 P.M.
Number of subjects: 0
Study: 484815

Group type: EXPERIMENTAL
Intervention: Caudal analgesia (1.5 mg/kg bupivacaine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular morphine (0.15 mg/kg)
Number of subjects: 40
Study: 31073952

Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGB)
Number of subjects: 45
Study: 28561068

Group type: EXPERIMENTAL
Intervention: GHB (35 mg/kg p.o.)
Number of subjects: 17
Study: 25887977

Group type: EXPERIMENTAL
Intervention: Repeated treatment with praziquantel and albendazole four times a year
Number of subjects: 765

Group type: COMPARATOR
Intervention: Single dose treatment with praziquantel and albendazole once a year
Number of subjects: 765
Study: 22959782

Group type: EXPERIMENTAL
Intervention: High-load strength training with protein supplementation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-load strength training with nonprotein supplementation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control period (no training)
Number of subjects: 29
Study: 21475970

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bupropion (300 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-Contingent Reinforcement (NR)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All groups (including CM and NR)
Number of subjects: 57
Study: 19575051

Group type: EXPERIMENTAL
Intervention: Polyamide polymer burs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Carbon steel round burs
Number of subjects: 40
Study: 17724558

Group type: EXPERIMENTAL
Intervention: Manual therapy twice a week for 4 weeks followed by stretching exercises
Number of subjects: 125

Group type: COMPARATOR
Intervention: Stretching 5 times a week for 4 weeks followed by manual therapy
Number of subjects: 125
Study: 16202254

Group type: EXPERIMENTAL
Intervention: Sibutramine tablet (10-20 mg/day for 24 weeks)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Sibutramine capsule (10-20 mg/day for 24 weeks)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study: 12456942

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11783214

Group type: EXPERIMENTAL
Intervention: Duodongining (DDN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ritalin
Number of subjects: 70
Study: 9213594

Group type: EXPERIMENTAL
Intervention: Laser flare meter (Kowa FM-500) used for monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: Postoperative period after uncomplicated keratoplasty
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acute allograft rejection treatment
Number of subjects: 50
Study: 2012051

Group type: EXPERIMENTAL
Intervention: Ranitidine administration
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ranitidine non-administration (Control)
Number of subjects: 35
Study: 6165217

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated women (control group)
Number of subjects: 0
Study: 30747394

Group type: EXPERIMENTAL
Intervention: SDPI‐DP lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control (Diabetes Prevention Program placebo group)
Number of subjects: 0
Study: 27842422

Group type: EXPERIMENTAL
Intervention: Blue-laser imaging (BLI)
Number of subjects: 127

Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 127
Study: 26418019

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 905

Group type: COMPARATOR
Intervention: Losartan-based treatment
Number of subjects: 905
Study: 23829442

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary educational group workshop including didactic lectures, value-clarification exercise, and patient discussions.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (informational booklet, website, patient volunteer if desired).
Number of subjects: 30
Study: 22962420

Group type: EXPERIMENTAL
Intervention: MES-guided placement of RV lead
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard apical placement of RV lead
Number of subjects: 50
Study: 20183664

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combination of CBT and FLX
Number of subjects: 439

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: All treatments (CBT, FLX, Combination, Placebo)
Number of subjects: 439
Study: 17576024

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 21

Group type: COMPARATOR
Intervention: PSV23
Number of subjects: 21
Study: 15182114

Group type: EXPERIMENTAL
Intervention: Telmisartan therapy (40-80 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study: 12455252

Group type: EXPERIMENTAL
Intervention: Family medicine preceptor
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: General internal medicine preceptor
Number of subjects: 464

Group type: COMPARATOR
Intervention: Generalist experiences during medical school
Number of subjects: 464
Study: 11477811

Group type: EXPERIMENTAL
Intervention: DF-521 with Heart-Brain Mixture (HBM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: DF-521 alone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 66
Study: 7653792

Group type: EXPERIMENTAL
Intervention: Enoximone (1.0 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: R80122 (0.3 mg/kg)
Number of subjects: 20
Study: 2702910

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (50 mg/dl)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normoglycemia (100 mg/dl)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (300 mg/dl)
Number of subjects: 18
Study: 362207

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (400 to 800 micrograms per day in divided doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alternate-day prednisone (20 to 40 mg on alternate mornings)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate and alternate-day prednisone (used together)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (7 children requiring only non-corticosteroid medication)
Number of subjects: 20
Study: 30502903

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 28557642

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 26

Group type: COMPARATOR
Intervention: 940 +/‐ 15‐nm diode laser
Number of subjects: 26

Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Scaling and root planing + Er,Cr:YSGG laser
Number of subjects: 26

Group type: COMPARATOR
Intervention: Scaling and root planing + 940 +/‐ 15‐nm diode laser
Number of subjects: 26

Group type: COMPARATOR
Intervention: Only scaling and root planing
Number of subjects: 26
Study: 25512461

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus TH-302 240 mg/m2 (G+T240)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus TH-302 340 mg/m2 (G+T340)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Gemcitabine (1,000 mg/m2)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 214
Study: 23334588

Group type: EXPERIMENTAL
Intervention: Menthol Camel crush for 15 days followed by non-menthol Camel crush for 15 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Own brand cigarette across all periods
Number of subjects: 32